

MAIL:dv 02/17/04 6947-67205 JEC/BP5795539

PATENT
Express Mail Label No. EV339200814US
Date of Mailing: February 17, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Brown *et al.*

Application No. 08/776,350

Filed: April 18, 1997

Confirmation No. 1818

For: TREATMENT OF CANCER USING HSV
MUTANT

Examiner: Susan Ungar, Ph.D.

Art Unit: 1642

Attorney Reference No. 6947-67205

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO
37 C.F.R. § 1.97(c)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are four English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Submitted herewith is a check for \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c).

Please charge any additional fees which may be required in connection with filing this IDS. Deposit Account authority is provided on the accompanying transmittal letter.

02/24/2004 MAHNE1 00000011 09776350

01 FC:1806


180.00 DP

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

By



Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6947-67205
Application Number	08/776,350
Filing Date	April 18, 1997
First Named Inventor	Brown
Art Unit	1642
Examiner Name	Susan Ungar, Ph.D.

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 96/39841	12/19/1996	PCT

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Kesari <i>et al.</i> , "Therapy of Experimental Human Brain Tumors Using Neuroattenuated Herpes Simplex Virus Mutant," <i>Laboratory Investigation</i> , 73(5):636-648, 1995
		Kucharczuk <i>et al.</i> , "Use of a "Replication-Restricted" Herpes Virus to Treat Experimental Human Malignant Mesothelioma," <i>Cancer Research</i> , 57:466-471, February 1, 1997
		Randazzo <i>et al.</i> , "Treatment of Experimental Intracranial Murine Melanoma with a Neuroattenuated Herpes Simplex Virus 1 Mutant," <i>Virology</i> , 211:94-101, 1995

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.